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Background: Combination therapy with inhaled corticosteroids (ICS) and long-acting b2-adren-
ergic agonists (LABA) is reported to have superior effects on controlling asthma symptoms to
ICS alone; however, there is no molecular-based evidence to explain the clinical effects. Here,
the effect of the ICS/LABA combination was compared with ICS on glucocorticoid receptor (GR)
activation in sputum macrophages.
Methods: In a randomised, double-blind cross-over placebo-controlled 6-visit study, 10 patients
with mild asthma were given placebo, formoterol (Oxis 12 mg), budesonide (Pulmicort 200 mg
:BUD200, or 800 mg :BUD800), or budesonide/formoterol combination (Symbicort) as a single
100/6 mg (SYM100) or double 200/12 mg (SYM200) dose. Sputum macrophages were separated by
plate adhesion from induced sputum. GR binding to the glucocorticoid-response elements on
oligonucleotides (GR-GRE binding) was evaluated by ELISA. mRNA expression of MAP-kinase
phosphatase (MKP)-1 and IL-8 were measured by quantitative RT-PCR.
Results: GR-GRE binding was significantly increased after treatment with SYM100 (3.5 OD/10 mg
protein, median, p < 0.05) versus placebo (1.3) and BUD200 (1.6), and the induction was higher
than that of BUD800 (2.4). MKP-1 mRNA was increased and IL-8 mRNA was significantly inhibited
by BUD800, SYM100 and SYM200 versus placebo.
Conclusions: The effects of SYM100 and SYM200 on GR activation were not different from that
of BUD800 and superior to BUD200. Thus, it has been confirmed at a molecular level that
inhaled combination therapy with a lower dose of budesonide has an equivalent effect to a high
dose of budesonide alone. In addition, GR-GRE binding is found to be a valuable pharmacody-
namic marker for steroid efficacy in clinical studies. (Registration No. NCT00159263)
ª 2011 Elsevier Ltd. All rights reserved.) 20 7352 8121x8389; fax: þ44 (0) 20 7351 8126.
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was 89% (4.0 SEM), fractional exhaled nitric oxide (FeNO)Figure 1 Study design. In this 6-arm randomised, double-
blind, cross-over placebo-controlled study, the patients were
given the drugs shown in Table 1 with a minimum of 2 days
washout period between treatments. Sputum was induced
1e2 h post inhalaton of study drugs or placebo and rescue
inhaler (200 mg salbutamol) was given 15 min prior to this
procedure. FEV1, was monitored four times in total: on arrival,
1 h after treatment then before- and after sputum induction.Asthma is a chronic inflammatory disease associated with
the expression of multiple inflammatory genes. Inhaled
corticosteroids (ICS) are the most effective anti-
inflammatory treatment for patients with persistent
asthma, however, recent evidence suggests that combina-
tion therapy of ICS and long-acting b2-adrenergic agonists
(LABA) controls asthma more effectively than ICS alone.1e3
Several studies show that the combination of low or
moderate doses of ICS with LABA leads to better asthma
control and a reduction in exacerbations compared to either
drug alone, and comparable or better than a higher dose of
ICS.4e6 However, the molecular mechanisms underlying
these enhancing effects of LABA on corticosteroid effects
remain to be fully elucidated. Several in vitro studies support
increased anti-inflammatory effects of corticosteroids in the
presence of LABA, including formoterol and salmeterol.7e10
As corticosteroids are potent anti-inflammatory agents,
cytokine inhibition has been used as a pharmacodynamic
marker to predict efficacy in clinical trials.11,12 Since
corticosteroids work via activation of the glucocorticoid
receptor (GR), we recently set up a new system to quantify
activation of GR. Once activated by ligand binding, GR
translocates to the nucleus and binds to glucocorticoid
response elements (GRE) on DNA. Activated GR also binds to
synthetic oligonucleotides containing the GRE site and can
be detected by enzyme-liked immunoassay using anti-GR
antibody.13 We have previously confirmed that this assay
system works in cultured cells and primary cells in vitro.13 In
the present study, GR-GRE binding was used as a molecular
corticosteroid pharmacodynamic marker. In addition, GR-
dependent mitogen-activated protein kinase phosphatae-1
(MKP-1) mRNA expression was used as a marker of GR-
dependent trans-activation14 and IL-8 suppression by corti-
costeroids as a marker of GR-dependent trans-repression.
Induction of sputum by inhalation of hypertonic saline
is a relatively non-invasive method to obtain inflammatory
cells or cytokines from the airways, compared to proce-
dures such as bronchoscopy and bronchial biopsies.15
Measurements of cell counts in sputum and biomarkers in
sputum supernatant have previously been used to inves-
tigate anti-inflammatory effects of glucocorticoids in the
airways of asthmatic patients. In the present study, we
measured GR-GRE binding activity in macrophages sepa-
rated from induced sputum samples.
In this study, our aim was to evaluate the dose-
dependent effects of inhaled budesonide on glucocorti-
coid pharmacodynamic markers, and also to compare the
effects of budesonide and formoterol combination therapy
with that of a high dose of budesonide alone, in sputum
macrophages from mild asthmatic patients.
Methods
Patient Population
10 patients with mild asthma, as defined by the GINA
guidelines,16 were enrolled. Female/Male ratio was 6/4 and
9 patients were atopic. Average age was 33 years old (3.0SEM). FEV1(Force Expelled Volume per second) % predicted
was 69 ppb (14.0 SEM). All patients used salbutamol on
demand. The study was approved by the Royal Brompton
and Harefield NHS Hospital Trust Ethics Committee, and
informed consent was given by all patients. (Registration
No. NCT00159263 http://www.clinicaltrials.gov).
Study design
At the screening visit to assess patients for suitability to
participate in the study, patient details and a short medical
history were recorded, and some simple measurements
performed. Thirteen patients in total were randomised and
screened for the study, three patients failed at screening
and ten patients completed the study.
In this 6-arm randomised, double-blind, cross-over,
placebo-controlled study (Fig. 1), the patients were given
the drugs via a multidose dry powder inhaler (Turbuhaler)
as shown in Table 1; placebo or single doses of Oxis for-
moterol 12 mg (formoterol; FM), Pulmicort budesonide
200 mg (budesonide; BUD200) or budesonide 800 mg
(BUD800), or budesonide/formoterol fixed combination
Symbicort (BUD/FM, Symbicort in one inhaler) 80 mg/4.5 mg
as a single dose (SYM100) or a double dose (SYM200), with
a minimum washout period of 2 days between each treat-
ment. Symbicort dose given is label claim on the basis of the
emitted dose from inhaler mouth piece, whereas Oxis and
Pulmicort - on the basis of the metered dose - and where
emitted dose is roughly equal to that in Symbicort for each
compound (i.e. the emitted BUD/FM 80 mg/4.5 mg dose is
equivalent to the metered 100 mg/6 mg dose).
Sputum was induced 1e2 h after inhalation of drugs,
when the GR-GRE binding activity peaks at, based on
preliminary results. As asthmatics are sensitive to sputum
induction, a rescue inhaler (200 mg of salbutamol) was given
15 min prior to this procedure. FEV1 was measured on
arrival, 1 h post treatment and then before and after
sputum induction. There was no difference in lung function
Figure 2 Lung Function. FEV1 was monitored 1 h post
treatment. All data are expressed as median, inter-quartile
range. **p  0.01 vs. placebo ##p  0.01 vs. Bud200.
Table 1 List of treatments and abbreviations.
Drug Dose Abbreviation
Placebo PLC
Formoterol 12 mga FM
Budesonide
low dose
200 mga BUD200
Budesonide
high dose
800 mga BUD800
Symbicort 80 mgb budesonide SYM100
4.5 mgb formoterol
Symbicort 2  80 mgb budesonide SYM200
2  4.5 mgb formoterol
a Dose given is label claim on the basis of the metered dose.
b Dose given is label claim on the basis of the emitted dose
from inhaler mouth piece; the emitted 80 mg budesonide and
4.5 mg formoterol doses are equivalent to 100 mg budesonide
and 6 mg formoterol metered doses.
1786 S. Essilfie-Quaye et al.tests when comparing pre/post sputum induction (data not
shown). Sputum macrophages were isolated from the
induced sputum by adhesion to a 6-well cell culture plate.
Sputum processing and macrophage separation
Sputum was induced in the patients using nebulised
hypertonic saline 1e2 h after inhalation of drug or placebo
as previously shown.11 Sputum collected from patients was
kept on ice or at 4 C for no more than 30 min. The sputum
sample was processed with freshly prepared 0.1% dithio-
threitol (DTT) as previously described.11 After processing,
the sputum cell pellet was resuspended in culture media
and macrophages were separated by adhesion to 6-well
high bound culture plates (Primaria surface treatment, 6-
well culture plate: BD Biosciences). Subsequently, cells
were collected as pellets and stored at 20 C, or nuclear
protein extraction or mRNA extraction was performed
immediately.
GR-GRE binding
Nuclear proteins were prepared using a nuclear extraction
kit (Active Motif, Rixensart, Belgium), and GR-GRE binding
activity was determined by Trans-AM kit (Active Motif) and
expressed in optical density (OD) units/10 mg protein.
MKP-1and IL-8 mRNA measurements
Total RNA extraction and reverse transcription procedures
were performed using an RNeasy kit (Qiagen, Crawley, UK)
and an Omniscript RT kit (Qiagen) respectively. Gene
transcript levels of MKP-1, IL-8 or GNB2L1, as a house-
keeping gene, were quantified by real-time PCR using
commercially available primers by a Taqman system
(Applied Biosystems, Warrington, UK) on a Rotor-Gene 3000
(Corbett Research, Mortlake, NSW, Australia).
The change in expression of MKP-1 or IL-8 gene
normalized to GNB2L1 over Placebo was determined by 2-
(DDC(T)) method.17Data analysis
All data are expressed as median, inter-quartile range.
Friedman ANOVA followed by Dunn’s pairwise comparisons
as used to analyse the results. p  0.05 was considered
statistically significant.
Results
Effects of treatment on FEV1
Nine out of the ten patients were found to be atopic with at
least one positive skin prick test from a group of common
allergens (grass pollen, house dust mite, cat and Aspergillus
fumigatus) when compared to saline as a negative control
and histamine as a positive control.
As shown in Fig. 2, FEV1 (expressed as % predicted)
measured 1 h after inhalation of placebo or drugs was signif-
icantly increased by 12 mg formoterol inhalation (97.0%,
91.7e110.1; median, inter-quartile range, p  0.001)
compared to placebo (83.1%, 75.1e98.8). FEV1 was also
significantly increased by SYM200 (97.5%, 85.2e107.0)
comparedwithplacebo. In contrast, budesonidealone (200mg
or 800 mg) did not show any effects on FEV1 and FEV1 after
treatment of SYM200 and FM was significantly higher
compared with BUD200.
GR-GRE binding activity after inhalation of
Symbicort was equivalent to that of a higher dose
of budesonide alone in sputum macrophages
GR-GRE binding activities in nuclear extracts were detect-
able in samples treated with placebo [1.31 OD, 0.38e2.06
(median, inter-quartile range)]. As shown in Fig. 3, GR-GRE
binding activity was significantly (p  0.05) increased after
800 mg budesonide treatment (2.42, 0.89e7.19) compared
with placebo, but not after 200 mg budesonide treatment.
In addition, GR-GRE binding activity was significantly
(p  0.05) increased after treatment with SYM100 (3.45,
1.48e6.43) compared to that of placebo and also compared
Figure 3 Effect of treatment on GR-GRE binding. GR acti-
vation was measured in sputum macrophages from mild asth-
matic patients treated with a study drug or placebo. Following
sputum processing and macrophage separation, nuclear
extracts were prepared and GR-GRE binding was detected
colour-metrically by an enzyme-immunosorbent assay method
and expressed in optical density (OD) units. All data are
expressed as median, inter-quartile range. *p  0.05,
***p  0.001.
Figure 4 Effect of treatment on MKP-1 mRNA expression.
MKP-1 mRNA expression was measured in sputum macrophages
from mild asthmatic patients treated with a study drugs or
placebo. Following sputum processing and macrophage sepa-
ration, total RNA extraction and reverse transcription were
performed. Gene transcript levels of MKP-1 was detected by
real-time qPCR were normalized to that of the housekeeping
gene GNB2L1, and analysed by 2-(DDC(T)) method over placebo.
All data are expressed as median, inter-quartile range.
*p  0.05, **p  0.01.
Figure 5 Effect of treatment on IL-8 mRNA expression. IL-8
mRNA expression was measured in sputum macrophages from
mild asthmatic patients treated with a study drugs or placebo.
Following sputum processing and macrophage separation, total
RNA extraction and reverse transcription were performed.
Gene transcript levels of IL-8 detected by real-time qPCR were
normalized to that of the housekeeping gene GNB2L1, and
analysed by 2-(DDC(T)) method over placebo. All data are
expressed as median, inter-quartile range. *p  0.05.
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with SYM200 (2.68, 1.60e6.31) also showed a significant
increase in GR-GRE binding compared with Placebo, but not
with BUD200. There was no difference in GR-GRE binding
activity between 800 mg budesonide treatment and SYM100
or SYM200 treatments.
MKP-1 gene expression was increased after
budesonide and budesonide/formoterol treatment
The mRNA expression levels of an anti-inflammatory gene,
MKP-1, weremeasured as amarker of GR trans-activation and
expressed as a ratio to a housekeeping gene (Fig. 4). For-
moterol alone did not induce MKP-1 gene expression
compared with placebo, but budesonide dose-dependently
increased MKP-1 gene induction (Fold change over Placebo:
BUD200 (3.12, 1.11e69.1, median, inter-quartile range,
p 0.05 vs placebo) andBUD800 (4.99, 1.83e49.9p 0.051)).
Symbicort also dose-dependently increased MKP-1 gene
induction compared with placebo; SYM100 (2.72, 1.00e154
p  0.05) and SYM200 (3.60, 1.69e148 p  0.05). There were
no statistically significant differences in the levels of the
gene induction between BUD800 and SYM (100 and 200).
IL-8 gene expression was reduced by budesonide
and budesonide/formoterol
The mRNA expression levels of a pro-inflammatory gene, IL-
8, were measured as a marker of GR trans-repression
(Fig. 5). Formoterol alone did not reduce IL-8 gene
expression compared with placebo. When compared with
placebo, IL-8 mRNA expression was decreased by inhalation
of both BUD200 (median, inter-quartile range : 0.44,
0.00043e1.89, not significant) and BUD800 (0.25,
0.000300e1.14, p  0.05) as well as SYM100 (0.13,0.000084e0.730, p  0.05) and SYM200 (0.341,
0.0000048e1.60, p  0.05). There were no statistically
significant differences in the levels of the gene suppression
between BUD and SYM.
Discussion
Cytokine production or inflammatory cell counts have been
used as pharmacodynamic (PD) markers of glucocorticoid
1788 S. Essilfie-Quaye et al.actions.11,12,18 However, PD markers based on glucocorti-
coid receptors have not been established. The GR-GRE
binding assay has previously been established in our labo-
ratory and used for cell culture work and primary cell
work.13 In this study, for the first time we have used this GR-
GRE system in a clinical study as a corticosteroid specific PD
marker. We also evaluated MKP-1 mRNA expression as
a functional readout for glucocorticoid-dependent gene
trans-activation and IL-8 gene expression to investigate
glucocorticoid-dependent gene trans-repression.
As shown in Figs. 3 and 4, inhaled budesonide dose-
dependently increased GR-GRE binding and MKP-1 mRNA
induction in macrophages isolated from induced sputum
obtained from mild asthmatic patients. Both MKP-1 induc-
tion and GR-GRE binding are useful PD markers of cortico-
steroid action and the MKP-1 expression assay appears to be
more sensitive than the GR-GRE binding assay. A prelimi-
nary study showed that at least 2 days of washout period is
necessary to achieve reproducible results (data not shown).
This is mainly due to a poor recovery of cell numbers after
a shorter washout period after sputum induction.
ICS are the most effective treatment for patients with
persistent asthma.19 Several clinical studies have shown
that the effects of ICS can be enhanced by LABA such as
formoterol and salmeterol, in mild, moderate and severe
asthma.5,20 In several in vitro systems, there is increasing
evidence that formoterol or salmeterol enhanced gluco-
corticoid effects.9,10 As shown in Figs. 3 and 4, the
effects of low dose budesonide/formoterol combination
(SYM100) were not different from the effects of a much
higher dose of budesonide (BUD800). This suggests that
formoterol indeed enhanced budesonide effects as for-
moterol alone did not show any effects on GR-GRE or
MKP-1 expression. SYM200 induced significant induction
of MKP1 gene, but neither BUD200 nor FM alone showed
significant induction. Thus, SYM200 is better than BUD200
or FM alone.
Similar to MKP-1, high dose of budesonide (BUD800) and
budesonide/formoterol combination (both SYM100 and
200) significantly reduced IL-8 mRNA expression. The low
dose of budesonide (BUD200) also gave an inhibition of
more than 50% although the efficacy was not significant.
Therefore, any superior effects of budesonide/formoterol
could not be detected as budesonide also strongly
reduced. Formoterol has been reported to not enhance
the effects of budesonide on IL-8 production by primary
bronchial epithelial cells,8,21 so IL-8 may be not a good PD
marker for detecting the greater benefit of combination
therapy. In addition, none of the drug treatments studied
affected IL-8 protein expression in sputum supernatant
(data not shown) but this is likely to be because we only
collected sputum at 1e2 h after drug treatments and this
may be too short time to detect drug effects on protein
levels of IL-8.Conclusions
Budesonide (200 mg and 800 mg) dose-dependently induced
glucocorticoid receptor activation (detected by GR-GRE
binding) and MKP-1 mRNA expression. The effects of
budesonide/formoterol (SYM100 and SYM200) wereequivalent to the high dose of budesonide (800 mg), sug-
gesting that formoterol enhanced budesonide effects on
gene activation. Thus, equivalent effects of combination
therapy with a low budesonide dose to those of a high dose
of budesonide alone were confirmed by molecular-based PD
markers. This suggests that combination inhalers with
budesonide and formoterol offer steroid-sparing and more
effective treatment in asthma management compared to
budesonide alone. In addition, this study shows that the
GR-GRE binding assay in sputum macrophages is a useful PD
biomarker for corticosteroids in clinical trials.
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